Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | May 05, 2020 | May 28, 2020 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director · President and CEO | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date May 05, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-05-04 | Direct | 30,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant.
PMV Pharmaceuticals, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2036-03-05 | Direct | 744,960 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 744,960 · Balance 744,960 F1: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 9, 2026 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 744,960 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001341642-26-000002 · form4-03092026_080314.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,960 Underlying: Common Stock · 744,960 shares Expires 2036-03-05 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 16:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 220,643 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001341642-25-000004 · form4-10292025_081048.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 220,643 shares Expires 2026-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 16:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 220,643 | $1.37 | $302,280.91 |
DisclosureSEC source: 0001341642-25-000004 · form4-10292025_081048.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Excludes 305,667 shares previously reported as held directly by the reporting person which were re-registered on August 13, 2025 and are now held of record by the Mack-Mulligan Revocable Trust (the "Revocable Trust"). Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 58,411 | $1.06 | $62,178.51 |
DisclosureSEC source: 0001415889-25-019380 · form4-07032025_110757.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,133 F1 · shares: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · balance_after: Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 18:30 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001415889-25-007071 · form4-03052025_110346.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2035-03-03 F5 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 22, 2025 16:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,709 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001415889-25-001853 · form4-01222025_090129.xml · derivative · entry 7 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,709 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| January 03, 2025 Filed Jan 22, 2025 16:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 17,709 | $0.53 | $9,385.77 |
DisclosureSEC source: 0001415889-25-001853 · form4-01222025_090129.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Jan 22, 2025 16:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 91,750 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001415889-25-001853 · form4-01222025_090129.xml · derivative · entry 6 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,709 Underlying: Common Stock · 91,750 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| December 03, 2024 Filed Jan 22, 2025 16:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 91,750 | $0.53 | $48,627.50 |
DisclosureSEC source: 0001415889-25-001853 · form4-01222025_090129.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:44 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 330,000 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-024622 · form4-10032024_081002.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2034-08-13 F7 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 330,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 330,000 shares, having an exercise price of $1.48 per share. F8 · derivative.exercise_date: One-fourth of the shares subject to the option vest on August 13, 2025 and 1/48th vest monthly thereafter. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:44 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 330,000 | Not disclosed Strike: $5.70 | Not disclosed |
DisclosureSEC source: 0001415889-24-024622 · form4-10032024_081002.xml · derivative · entry 4 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 330,000 shares Expires 2033-05-12 F7 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 330,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 330,000 shares, having an exercise price of $1.48 per share. F6 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:44 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 384,184 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-024622 · form4-10032024_081002.xml · derivative · entry 3 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,184 Underlying: Common Stock · 384,184 shares Expires 2034-08-13 F2 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 134,584 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 134,584 shares, having an exercise price of $1.48 per share. F4 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 249,600 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 249,600 shares, having an exercise price of $1.48 per share. F5 · derivative.exercise_date: One-third of the shares subject to the option vest on August 13, 2025 and 1/36th vest monthly thereafter. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:44 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 249,600 | Not disclosed Strike: $16.29 | Not disclosed |
DisclosureSEC source: 0001415889-24-024622 · form4-10032024_081002.xml · derivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 249,600 shares Expires 2032-02-10 F4 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 249,600 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 249,600 shares, having an exercise price of $1.48 per share. F3 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:44 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 134,584 | Not disclosed Strike: $28.33 | Not disclosed |
DisclosureSEC source: 0001415889-24-024622 · form4-10032024_081002.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 134,584 shares Expires 2031-05-11 F2 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 134,584 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 134,584 shares, having an exercise price of $1.48 per share. F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 16:02 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 519,915 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-24-001993 · doc4.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,915 Underlying: Common Stock · 519,915 shares Expires 2034-01-18 F4 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 18, 2024. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 16:02 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantCommon Stock | 163,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001993 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,460 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 30, 2025. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 16:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 85,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054997 · doc4.xml · nonDerivative · entry 3 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 165,307 F1 · ownership.nature: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 16:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 85,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054997 · doc4.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,570 Read SEC document |
| October 18, 2023 Filed Nov 13, 2023 16:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 198,407 | $0.53 | $105,155.71 |
DisclosureSEC source: 0001209191-23-054997 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 16:43 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 85,500 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-23-045010 · doc4.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,866 Underlying: Common Stock · 85,500 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 16:43 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 85,500 | $0.53 | $45,315.00 |
DisclosureSEC source: 0001209191-23-045010 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Nov 13, 2023 16:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 198,407 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-23-054997 · doc4.xml · derivative · entry 6 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,459 Underlying: Common Stock · 198,407 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 12, 2023 Filed May 15, 2023 17:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-029586 · doc4.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2033-05-12 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 21:15 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-22-026341 · doc4.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,366 Underlying: Common Stock · 33,000 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. F5 · balance_after: Due to an administrative error, the Form 4 filed on May 24, 2021 overstated the number of derivative securities beneficially owned following the reported transaction by 6,207 shares and has been updated in this Form 4 to correct the error. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 21:15 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 33,000 | $0.53 | $17,490.00 |
DisclosureSEC source: 0001209191-22-026341 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001209191-22-017591 · doc4.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,644 Underlying: Common Stock · 20,000 shares Expires 2026-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 20,000 | $1.37 | $27,400.00 |
DisclosureSEC source: 0001209191-22-017591 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 28, 2022 16:12 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 249,600 | $0.00 Strike: $16.29 | $0.00 |
DisclosureSEC source: 0001209191-22-013544 · doc4.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,600 Underlying: Common Stock · 249,600 shares Expires 2032-02-10 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:57 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-070116 · doc4.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,574 Underlying: Common Stock · 9,000 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:57 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 9,000 | $0.53 | $4,770.00 |
DisclosureSEC source: 0001209191-21-070116 · doc4.xml · nonDerivative · entry 3 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2021 Filed Dec 16, 2021 21:57 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070116 · doc4.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 40,000 F2 · ownership.nature: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 16, 2021 21:57 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070116 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 187,915 F1 · ownership.nature: The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:41 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-052787 · doc4.xml · derivative · entry 4 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,574 Underlying: Common Stock · 5,500 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:41 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 5,500 | $0.53 | $2,915.00 |
DisclosureSEC source: 0001209191-21-052787 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 16:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 26,767 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-047745 · doc4.xml · derivative · entry 8 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,074 Underlying: Common Stock · 26,767 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 16:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 26,767 | $35.76 | $957,091.56 |
DisclosureSEC source: 0001209191-21-047745 · doc4.xml · nonDerivative · entry 4 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,470 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $36.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 16:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 26,767 | $0.53 | $14,186.51 |
DisclosureSEC source: 0001209191-21-047745 · doc4.xml · nonDerivative · entry 3 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 16:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 1,029 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-047745 · doc4.xml · derivative · entry 7 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,841 Underlying: Common Stock · 1,029 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 16:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,029 | $35.53 | $36,560.37 |
DisclosureSEC source: 0001209191-21-047745 · doc4.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,470 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 16:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 1,029 | $0.53 | $545.37 |
DisclosureSEC source: 0001209191-21-047745 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 18:09 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 204 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-043738 · doc4.xml · derivative · entry 5 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,870 Underlying: Common Stock · 204 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 18:09 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 204 | $35.53 | $7,248.12 |
DisclosureSEC source: 0001209191-21-043738 · doc4.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,470 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 18:09 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 204 | $0.53 | $108.12 |
DisclosureSEC source: 0001209191-21-043738 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 24, 2021 16:52 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 6,207 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-035364 · doc4.xml · derivative · entry 8 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,074 Underlying: Common Stock · 6,207 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 21, 2021 Filed May 24, 2021 16:52 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 6,207 | $35.71 | $221,641.42 |
DisclosureSEC source: 0001209191-21-035364 · doc4.xml · nonDerivative · entry 4 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.99, inclusive. Read SEC document |
| May 21, 2021 Filed May 24, 2021 16:52 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 6,207 | $0.53 | $3,289.71 |
DisclosureSEC source: 0001209191-21-035364 · doc4.xml · nonDerivative · entry 3 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed Jun 4, 2021 19:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-038419 · doc4.xml · derivative · entry 4 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,074 Underlying: Common Stock · 10,000 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:52 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 7,793 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-035364 · doc4.xml · derivative · entry 7 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,867 Underlying: Common Stock · 7,793 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:52 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 7,793 | $35.60 | $277,454.96 |
DisclosureSEC source: 0001209191-21-035364 · doc4.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:52 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 7,793 | $0.53 | $4,130.29 |
DisclosureSEC source: 0001209191-21-035364 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.